Examination of reduction of hepatic fat mass and hepatic fibrosis inhibitory effect of pemafibrate in type 2 diabetic patients with hyperlipidemia and non-alcoholic fatty liver
Latest Information Update: 02 Jun 2021
At a glance
- Drugs Pemafibrate (Primary)
- Indications Hyperlipidaemia; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Expectation Trial
- 02 Jun 2021 New trial record